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Background: Central Europe presents with the highest incidence of sporadic colorectal cancer (CRC) worldwide. As
sporadic CRC represents a typical multifactorial disease, it is characterized by intense interaction of the genetic
background with the environment. Glutathione S-transferases could act as attractive susceptibility genes for CRC, as
they are directly involved in conjugation between glutathione and chemotherapeutics, environmental pollutants
and a wide spectrum of xenobiotics.
Methods: In this study, we investigated associations of polymorphisms in glutathione S-transferases (GSTs) genes,
that is GSTA1, GSTT1, GSTM1 and GSTP1, with CRC in a total of 197 cases and 218 controls originating from the
Czech Central European population. Polymorphisms were assessed by polymerase chain reaction/restriction
fragment length polymorphism-based methods, allele-specific multiplex and allelic discrimination by real-time
polymerase chain reaction.
Results: None of investigated polymorphisms showed any associations with CRC, with the exception of GSTP1;
where the heterozygote genotype Ile105Val was associated with decreased risk of CRC (P= 0.043).
Conclusions: The frequencies observed in our study are in accordance with those from other European Caucasian
populations. Based on our studies, examined variability in GST genes is not a major determinant of CRC
susceptibility in the Central European population.
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Colorectal cancer (CRC) represents the third most fre-
quent type of cancer among males and the second most
common cancer in females worldwide. Worldwide, every
year, more than 1 million individuals will develop colo-
rectal cancer and the disease-specific mortality rate is
nearly 33% in the developed world [1], making the dis-
ease a substantial health as well as economic burden on
society. Sporadic CRC is a typical multifactorial disease
arising from maladaptive interaction between genetic
background and certain environmental factors, such as* Correspondence: on.slaby@gmail.com
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reproduction in any medium, provided the ordiet or lifestyle, however, the exact role of the genetic
background to sporadic CRC remains unclear.
Glutathione S-transferases (GSTs) represent a superfamily
of phase II metabolic enzymes that catalyze the conjugation
between glutathione and chemotherapeutic drugs, carcino-
gens, environmental pollutants, and a broad spectrum of
xenobiotics. GSTs are involved in the metabolism of isothia-
cyanates (ITCs), naturally occurring molecules that were re-
cently shown to inhibit development of tumors in many
experimental models [2] and that also induce apoptosis in
human colon cancer cells [3]. GST izoenzymes are encoded
by three separate families of genes (designated cytosolic,
microsomal and mitochondrial transferases), with distinct
evolutionary origins, which provide mammalian species
with protection against electrophiles and oxidative stressors
in the environment. Members of the cytosolic class Alpha,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ferases (MGST2 and MGST3), are upregulated by a diverse
spectrum of foreign compounds typified by phenobarbital,
1,4-bis[2-(3,5-dichloropyridyloxy)] benzene, pregnenolone-
16α-carbonitrile, 3-methylcholanthrene, 2,3,7,8-tetrachloro-
dibenzo-p-dioxin, β-naphthoflavone, butylated hydroxyani-




The polymorphisms in these genes lead mostly to re-
duction of enzymatic activity, for example, homozygotes
for polymorphisms C69T in GSTA1 genes have reduced
enzymatic activity compared to the wild-type homozy-
gotes [4]. Also GSTP1, the most frequently distributed
GST isoenzyme [5], harbors a functional polymorphism
(rs1695, Ile105Val) [6] resulting in a lower enzyme activ-
ity [7]. Null genotype with no enzymatic activity in
GSTM1 gene was reported in 40 to 60% of Caucasians
[8] and GSTT1 null genotype is present at a frequency
of 10 to 20% in Caucasian population [9]. Individuals
with reduced GST enzymatic activity may present with
decreased metabolism of ITCs, which could result in an
increased pool of ITCs and, therefore, modified CRC
risk.
The Central European population represents a popula-
tion with extremely high incidence of CRC [10] and it
could well serve as a model population for the study of
the genetic background to CRC. The role of GST izoen-
zymes has been already studied in the Czech population
of 495 CRC patients in a larger multicentric study. The
aim of our study was to replicate these findings on a
smaller, highly homogeneous cohort [11] of CRC
patients, that is, to determine whether common genetic
polymorphisms in the most important isoenzymes of the
GST family (GSTA, GSTM1, GSTP1 and GSTT1) predis-




De novo diagnosed cases of CRC treated at the Masaryk
Memorial Cancer Institute, Czech Republic, between Janu-
ary 2008 and December 2010 were enrolled into this study.
The cases comprised a total of 197 subjects [105 men, 92
women; age (mean±SD): 63±9 years) with the histologi-
cally confirmed diagnosis of CRC, whereas the control
group included 218 cancer-free blood donor volunteers
recruited from the same institute, had a similar age distri-
bution (96 men, 122 women; mean age: 66±16 years) and
had no previous personal history of cancer. Colonoscopy
was not performed in controls to exclude CRC, but all sub-
jects were symptom-free and presented with no anemia. All
subjects had the same ethnicity (Caucasian). Writteninformed consent approved by the local ethical review
board was obtained from all subjects and was archived.DNA isolation and genotyping
Genomic DNA was isolated from whole peripheral blood
using MagNA Pure DNA Isolation Kit (Roche Applied
Science, Indianapolis, IN, USA). DNA concentration was
measured on Nanodrop ND-1000 (NanoDrop Technolo-
gies Inc., Wilmington, DE, USA).
For analyses of SNPs rs1695 in GSTP1 Ile105Val real-
time PCR allelic discrimination was performed on a
StepOne Real-Time PCR instrument (Life Technologies,
Applied Biosystems, Carlsbad, CA, USA) using standard
TaqMan genotyping assays according to the manufac-
turer’s instructions (Assay ID: C 3237198_20).
The analysis of the GSTA1 C69T SNP was performed
using PCR-restriction fragment length polymorphism
(RFLP) according to [12]. A 400-bp fragment was
amplified with the forward and reverse primers for
GSTA1 (F: 5′-GCATCAGCTTGCCCTTCA-3′; R: 5′-
AAACGCTGTCACCGTCCTG-3′). PCR was performed
with a total volume of 12.5 μl with 0.1 μg genomic
DNA, 0.1 μM each primer, 0.2 mM each dNTP and 0.35
unit Taq DNA polymerase in 1x buffer supplied with
the polymerase. Thermocycler parameters included an
initial five-minute denaturation step at 94°C followed
by thirty cycles of denaturation (94°C/20s), annealing
(64°C/20s) and extension (72°C/30s). A final seven-
minute extension was performed before cooling reaction
to 4°C. All amplification steps were completed using
PTC-200 Peltier thermal cycler (Bio-Rad Laboratories
Inc, Hercules, CA USA). For RFLP analysis, 5 μl of PCR
product was digested using 0.5 unit restriction enzyme
Ear I with 1x buffer Tango (Fermentas Inc., Glen Burnie,
MD, USA) supplied with restriction enzyme in total
volume of 20 μl. Digestion was performed for 12 hours
at 37°C; digestion was stopped by incubation at 65°C for
20 minutes. These digested products were separated on
2% agarose gel stained with ethidium bromide for
40 minutes. The wild-type allele (C) had no Ear I site
and was still 400 bp. A 92-bp nucleotide was removed
from the variant allele (T), which yielded in a 308-bp
fragment.
Genotyping of GSTM1 and GSTT1 deletions was car-
ried out using a duplex PCR with the Albumin gene
serving as an internal positive control. The total reaction
volume was 12.5 μl containing 0.1 μg genomic DNA,
0.35 units of Taq DNA polymerase (Fermentas Inc., Glen
Burnie, MD, USA) in 1x Taq buffer supplied with poly-
merase, 0.1 μM each primer (GSTM1_F, GSTM1_R,
ALB_F, ALB_R, or GSTT1_F, GSTT1_R, ALB_F, ALB_R)
and 0.2 mM each dNTP. The sequence of reverse and
forward primers were as follows:







All primers were synthesized at Integrated DNA Tech-
nologies Inc., Coralville, IA, USA. PCR conditions were
the same as for the amplification of GSTA1 mentioned
above. The PCR products were analyzed on the 2% agar-
ose gel stained with ethidium bromide for 40 minutes at
100 V. The wild-type genotype for GSTM1 corresponded
to 215 bp, GSTT1 to 480 bp and the 380 bp corre-
sponded to the Albumin gene, which was used as
internal control to prove the successful PCR amplifica-
tion [13,14].Statistical analysis
Results were evaluated in the Statistica version 9.0 pro-
gram (StatSoft, Inc, Tulsa, OK, USA). Hardy-Weinberg
equilibrium was tested for each polymorphism calculat-
ing χ2 test for the patients and the controls separately.
When calculating odds ratio (OR), the homozygote of
the most frequent allele was used as a reference. For
odds ratio and 95% confidence interval, unconditional
logistic regression was used based on a model adjusted
for sex and age of patients. The values of P< 0.05 were
considered statistically significant.Results
All investigated polymorphisms were in Hardy-
Weinberg equilibrium. The frequencies of GST geno-
types by case-control status and the association of GST
polymorphisms with CRC are shown in Table 1. An un-
conditional logistic regression model was employed to
compare the genotype and allele frequencies of SNPs in
GSTP1 (rs1695, Ile105Val), GSTA1 (C69T substitution)
and deletion in GSTM1 and GSTT1 genes between the
cases and the controls. There were no significant differ-
ences in allele and genotype distributions between the
investigated cohorts. A logistic regression model was
used to identify the OR of the CRC of investigated gen-
etic variants. The subjects carrying heterozygous geno-
type of GSTP rs1695: A>G had significantly decreased
risk of CRC (OR 0.64; 95% CI: 0.42 to 0.98, P= 0.043)
compared to AA homozygotes. The frequency of AG
heterozygotes of GSTP1 rs1695 was lower in CRC
patients than in healthy controls (37.56% versus 45.87%),
G allele-containing genotypes (AG and GG) showed a
similar tendency in their frequencies (28.93% in CRC
versus 34.40% in controls). The investigated polymorph-
isms in GSTA1 as well as GSTM1 and GSTT1 genesfailed to show a statistically significant association with
CRC risk.
Discussion
In this study, we investigated the possible role of common
GST polymorphisms in the development of CRC in the
Central European Caucasian population, a population with
the highest incidence of CRC worldwide. The reports on
GST polymorphisms as potential risk factors for CRC are
controversial [15]. Based on this large meta-analysis of
SNPs in GSTM1, GSTT1, GSTP1 and GSTA1 genes, the
GSTM1 as well as GSTT1 null allele carriers should ex-
hibit increased CRC risk in Caucasian populations.
However, the only significant association from our
study refers to the GSTP1 Ile105Val polymorphism, for
which no significant associations were reported in large
pooled Chinese or Caucasian cohorts [15], with an
exception of a very small Bulgarian population [16]. Sur-
prisingly, the frequencies of GSTP1 genotypes observed
in our study were significantly different between our
study and another study on a Czech population men-
tioned above [11] (52.2% vs. 45.1%) and the frequency of
heterozygotes was also markedly different between these
two cohorts (37.6% vs. 46.3%).
On the whole, the frequencies of examined poly-
morphism in our study corresponded well with other
European cohorts. The frequencies of GSTA1 poly-
morphism in our population were similar to the fre-
quencies in a Dutch cohort [17], frequencies of GSTT1
genotypes were slightly below the frequencies reported
for the Scottish [18] population. The frequencies of
GSTM1 genotypes also corresponded well to the Dutch
[17] and Scottish cohort [18]. As for the genotype fre-
quencies of rs1695 in GSTP1 gene, the AA genotype was
significantly more frequent in our cohort than in the
Dutch study (52.2% vs. 42.5%), however, less frequent
than in the Bulgarian study [16] (52.2% vs. 69.0%).
When comparing the frequency of GSTM1 null allele
in CRC cases between our study and the study by Hla-
vata et al. [11], significant differences were observed for
the GSTM1 null allele (53.9% vs. 50.8%), while frequency
of GSTT1 null allele was almost identical between our
study and their study (20.8% vs. 20.3%).
As mentioned above, in this study we observed a sig-
nificantly decreased CRC risk associated with heterozy-
gosity in GSTP1 locus. The biological relevance of this is
unclear. It has to be mentioned that the low-expression
variant (GG) of this polymorphism is expressed in a re-
cessive manner, thus both alleles have to be present to
express the trait. The possible explanation for the pro-
tective effect associated with heterozygosity in GSPT1
locus could be an unknown advantage of the heterozy-
gotes related to yet undiscovered mechanisms of protec-
tion against sporadic CRC. In the above mentioned
Table 1 Logistic regression analyses of genotype frequencies of SNPs GSTP1 (rs1695), GSTA1 and deletion in GSTM1
and GSTT1 in colorectal cancer cases and controls from a Czech population
Control CRC
N % N % OR*** 95% Cl P-value
GSTA1 (C69T) CC 76 34.8 69 35,0 1.00 0.981*
CT 108 49.5 99 50.3 1.04 (0.67–1.60) 0.847**
TT 34 15.6 29 14.7 1.03 (0.56–1.90) 0.960**
Trend 218 197 1.02 (0.76–1.37) 0.887*
GSTT1_del wt 179 82.1 157 79.7 1.00 0.531*
del 39 17.9 40 20.3 1.13 (0.69–1.86) 0.711**
Trend 218 197 1.13 (0.69–1.86) 0.531*
GSTM1_del wt 117 53.7 97 49.2 1.00 0.262*
del 101 46.3 100 50.7 1.25 (0.84–1.86) 0.276**
Trend 218 197 1.25 (0.84–1.86) 0.263*
GSTP1 (Ile105Val,rs1695) AA 93 42.6 103 52.3 1 0.095*
AG 100 45.9 74 37.6 0.64 (0.42–0.98) 0.043**
GG 25 11.5 20 10.2 0.67 (0.35–1.28) 0.266**
Trend 218 197 0.76 (0.56–1.02) 0.062*
*LR-test.
**Wald’s test.
***Age and sex adjusted.
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observed for Ile105Val polymorphism in GSTP1 locus
(OR 1.01, 95%CI, 0.77 to 1.32, P= 0.944), but a similar
trend for the GSTM1 deletion and its association with
CRC risk was observed (OR 1.30, 95% CI 1.01 to 1.68,
P= 0.044), which can be easily explained by the similar
ethnic origin of both the cohorts [11].
Limitations of the study include a significant lack of data
on phenotypic effects of GST family genes, which makes
further functional studies a necessity to determine the
exact genotype-phenotype correlation, with special atten-
tion paid to the dietary composition, mainly in terms of
the amount of isothiocyanates in the diet. It may be
suggested that our results are affected by selection bias,
however, the patients and the controls were included in
the study randomly, as they arrived at the clinic. Also, it
should be mentioned that the present study was carried out
on a relatively static population from Moravia, part of the
Czech Republic settled by a Central European Caucasian
population of Slavonic origin that can be assumed to be
homogeneous, and that was previously associated with ex-
treme rates of CRC compared to other populations.Conclusions
Frequencies of the polymorphisms in GST genes
observed in our study are in accordance with those from
other European Caucasian populations. Our data do not
provide a robust evidence that investigated polymorphisms
in GST genes act as major modulators of genetic suscepti-
bility to CRC in the Central European population.Competing interests
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